Angle names exec chairman, and other proposed changes

Shares of UK precision CTC intelligence company Angle (AIM: AGL) were down more than 16% at 2.30 pence in early trading as it revealed a number of changes.

First, Angle announced that its chairman, Dr Jan Groen, has moved into an executive role. He will lead the company as it pursues a revised strategy, focused on tight cost control, accelerated commercial progress and a clear plan towards becoming a sustainable business.

Mr Groen has over 25 years of experience in the commercialization of clinical and personalized oncology diagnostics, and has led the turnaround of several companies, one of them being a publicly listed company, Oncomethylome Science, that has continued successfully after its restructure as MDxHealth (Nasdaq: MDXH). Mr Groen is working alongside the senior management team to identify the appropriate ongoing cost base whilst progressing a number of potential collaborations and partnerships that were detailed in the interim results in early September.